-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
-
India's Retail Inflation Reaches 6.09% as Food Prices Accelerate
-
India's Wholesale Inflation Jumps to 12.29% as Fuel Costs Surge
-
China's October Activity Data Reveal a Weak Start to the Fourth Quarter
-
Japan's Economy Edges Into Contraction as Costly Oil Weighs on Demand
-
Philippines Urges ASEAN and China to Accelerate South China Sea Code of Conduct
-
South Korea Launches Probe into NewJeans Contract Controversy
-
Met Office Issues Yellow Snow Warning for Nottinghamshire on Tuesday
-
UK Defence Secretary Warns Russia Nukes Not for Negotiation as HMS Vengeance Returns
-
Rescue Intellitech Expands Professional Decontamination Portfolio for Fire Departments with DeconWasher(TM) Pro S
-
GameSquare Holdings Reports 2026 Third Quarter Results with Revenue up 77% YoY and Net Income Reaches $10.1 Million
-
ValorPay UAB Goes Live on T2, the Eurosystem's Real-Time Settlement System
-
NuRAN Wireless Eliminates Floating-Price Preferred Overhang and Locks In a Fixed C$1.20 Conversion Price
-
CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline
-
XCF Global Reports Third Quarter 2026 Financial Results & Affirms 2027 Outlook
-
NextSource Materials Appoints Eugene Lee as Chief Financial Officer
-
International Battery Metals Ltd. Reports Second Quarter of Fiscal Year 2027 Financial Results
-
Abasca Resources Engages Northern Arc Public Affairs to Advance Federal Engagement on the Loki Flake Graphite Project
-
AsiaFIN Holdings Corp. Announces Third Quarter 2026 Results, Reporting Strong Nine-Month Financial Performance with Improved Margins
-
Thalia Therapeutics PLC Announces Promising Interim Phase I Data for miRisten in AML
-
Strategic Metals Reports Promising Results From the Rusty and Ranch Projects
-
Golden Minerals Reports Third Quarter 2026 Financial Results
-
OBI Pharma Signs Collaboration and License Agreement with Novartis
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 16
-
Blue Chip Capital Group Announces Quotation of its Common Stock on the OTCID and Updates Status of Initial Regulatory Compliance
-
Cardiff Lexington Announces Third Quarter 2026 Financial Results
-
Emerging Growth Research Highlights Criticality of First Phosphate G7-Backed LFP Battery Onshoring Solution as Cleantech Sector Accelerates Post U.S. Midterms
-
Presidio Property Trust, Inc. Announces Earnings for the Quarter Ended September 30, 2026
-
Sekur Private Data Ltd. Provides Update on Expected Closing of Non-Brokered Private Placement
-
iFabric Corp Announces Record Revenues for Q3 2026 and the Nine Months Ended September 30, 2026
-
RenX Enterprises Reports Record Third Quarter Revenue of $4.49 Million, Up 27.6% Year Over Year
-
Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
-
Gladstone Capital Corporation Earnings Call and Webcast Information
-
Sharecare Partners With HomeTown Health to Bring AskMD, Funded Through the GREAT Health Program, to More Rural Hospitals and Patients Across Georgia
-
Wi2Wi Reports 35% Revenue Growth to US$2.36M and Returns to Profitability with US$268K Net Income in Q3 2026
-
Ainos Reports Third Quarter 2026 Results and Highlights Expanding AI Nose Commercial Momentum
-
SMX Brings a New Level of Transparency to Gold Trading Through trueGold Technology
-
Westell Technologies, Inc. Announces Its Commencing a Tender Offer
-
MicroVision Lidar Powers Commercial Driverless Trucking at Scale with Kodiak AI
-
Expecting a Refund but Owe Back Taxes? Clear Start Tax Explains How the IRS Offset Program Takes It First
-
SMX: The Future of Gold Will Be Defined by What We Know About It -Powering Verified Trade and Tokenisation
-
Poll Shows Two-Thirds of New York Voters Support Lifting Charter School Cap
-
Park Jin-young Denies Cult Allegations Against Firstfruits Group
-
Downing Street Defends PM's Speechwriting After AI Photo Emerges
CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline
Company has been exploring multiple acquisition and licensing opportunities, with the goal of securing first transaction by year-end
$17.2 million cash position provides financial strength to support strategic execution and planned operations
HOUSTON, TX / ACCESS Newswire / November 16, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2026 and provided an update on its corporate strategy.
CNS Pharmaceuticals continues to make meaningful progress in executing its pipeline expansion strategy, advancing discussions with potential counterparties regarding the acquisition or licensing of innovative therapeutic assets in neurology, oncology or rare disease. The Company remains focused on completing its first pipeline-building transaction by year-end 2026, an important anticipated milestone in its strategic transformation.
"We are approaching an important inflection point in the evolution of CNS Pharmaceuticals," said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals. "Our efforts to identify and evaluate compelling therapeutic opportunities have progressed into advanced discussions with potential counterparties, bringing us closer to establishing the foundation of our next-generation pipeline. We are encouraged by the quality of the opportunities under consideration and remain intensely focused on translating these discussions into a meaningful transaction. Our objective is clear: secure a differentiated asset with the potential to drive clinical development, establish a platform for future growth and create long-term shareholder value. We look forward to delivering on this important strategic priority."
Third Quarter 2026 Financial Results
Research and development expenses were approximately $0.9 million for the third quarter of 2026, compared to approximately $2.2 million for the same period in 2025. The decrease was primarily attributable to lower clinical costs related to Berubicin following the completion of enrollment and patient treatments in its clinical trial, as well as lower TPI 287 manufacturing costs. These decreases were partially offset by increased personnel-related expenses. Future research and development expenses will depend on the timing and nature of any assets the Company in-licenses or acquires and the associated development activities.
General and administrative expenses were approximately $1.8 million for the third quarter of 2026, compared to approximately $1.1 million for the same period in 2025. The increase was primarily attributable to higher consulting expenses, mainly related to business development, and increased personnel-related expenses, partially offset by lower professional services expenses.
Net loss for the third quarter of 2026 was approximately $2.5 million, or $0.24 per basic and diluted share, compared to a net loss of approximately $3.2 million, or $5.76 per basic and diluted share, for the third quarter of 2025.
Cash and cash equivalents were approximately $17.2 million as of September 30, 2026, compared to approximately $7.2 million as of December 31, 2025. The increase primarily reflects net proceeds from the Company's previously announced $22.5 million private placement financing completed in May 2026. The Company believes that its cash resources, including the net proceeds from the May 2026 financing, are sufficient to fund its planned operations beyond the next twelve months.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.
For more information, please visit www.CNSPharma.com, and connect with the Company on X and LinkedIn.
Forward-Looking Statements
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the Company's strategic transformation and pipeline development plans, the Company's ability to identify, acquire and advance new therapeutic assets, expectations regarding the Company's ability to create long-term shareholder value, and the timing related to the execution of the Company's strategy. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risk that current discussions may not result in a definitive transaction, that any acquired or licensed asset may not achieve clinical or commercial success, that additional capital may be required to fund future operations or transactions, as well as market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the SEC and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]
Business Development Contact
CNS Pharmaceuticals, Inc.
Dylan Wenke, Chief Business Officer
[email protected]
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
B.Finley--AMWN